ライフサイエンスコーパス: diagnostic agent

1 l acute respiratory distress syndrome (ARDS) diagnostic agent.

2 ied for developing targeted chemotherapy and diagnostic agents.

3 used approach to prepare molecular tools and diagnostic agents.

4 produced and examined as potential companion diagnostic agents.

5 Nanoparticles are frequently suggested as diagnostic agents.

6 ghly specific toxin-specific therapeutic and diagnostic agents.

7 prove delivery efficiency of therapeutic and diagnostic agents.

8 inding ligands for targeted therapeutics and diagnostic agents.

9 g, and controlled release of therapeutic and diagnostic agents.

10 sites, and/or 3) delivering therapeutic and diagnostic agents.

11 ide a novel delivery system for contrast and diagnostic agents.

12 ons in biosciences, including as imaging and diagnostic agents.

13 dalities for the delivery of therapeutic and diagnostic agents.

14 gateway for the delivery of therapeutic and diagnostic agents.

15 and can provide insights into developing new diagnostic agents.

16 seful for the design of both therapeutic and diagnostic agents.

17 In fatal cases, diagnostic agents (28.7%) and antibiotics (23.9%) were t

18 Delivery of therapeutic or diagnostic agents across an intact blood-brain barrier (

19 that functions as a combined therapeutic and diagnostic agent against cancer.

20 ave considerable potential as therapeutic or diagnostic agents against many neurological diseases.

21 could be a very early, highly specific ARDS diagnostic agent and may be useful to detect a wide rang

22 sense-based or antigene-based genetic tools, diagnostic agents and drugs, especially for those situat

23 particles are used as therapeutic as well as diagnostic agents and improved dose localization within

24 unning occurs due to 74 MBq (131)I used as a diagnostic agent before (131)I ablation, it has no signi

25 ing avenue for the design of therapeutic and diagnostic agents, but the limited understanding of thei

26 in nanomedicine as drug delivery vectors and diagnostic agents, but the skin toxicity and irritation

27 Not limited to anticancer drugs, diagnostic agents can also be achieved with these renal

28 been demonstrated to enable incorporation of diagnostic agents, drugs, and nucleic acids such as siRN

29 for specific delivery of antitumor drugs and diagnostic agents due to its overexpression in prostate

30 t multiple types of therapeutic drugs and/or diagnostic agents (e.g., contrast agents) could be deliv

31 tion of P.pAb, utility as a plasma biomarker/diagnostic agent for AD was assessed using a single mole

32 m)Tc-PHC-102 might also serve as a companion diagnostic agent for future CAIX-targeting therapeutics.

33 M. leprae ESAT-6 shows promise as a specific diagnostic agent for leprosy.

34 her (pre)clinically developed as a companion diagnostic agent for patient stratification in trials wi

35 armaceutical that has been investigated as a diagnostic agent for the assessment of androgen receptor

36 ters for Disease Control and Prevention as a diagnostic agent for the causative agent of plague.

37 disease, and efficient therapeutic and early diagnostic agents for AD are still lacking.

38 ad compounds for the development of improved diagnostic agents for AD.

39 e development of new therapeutic VNAs and/or diagnostic agents for anthrax.

40 d lead to the development of new imaging and diagnostic agents for cancer.

41 molecular probes can be developed as in vivo diagnostic agents for melanoma and its metastases.

42 t further development of (68)Ga-PSMA-R2 as a diagnostic agent in patients with PC.

43 The most frequent causes of AN were diagnostic agents including X-ray contrast media (20.3%)

44 lyte affinity capture by surface-immobilized diagnostic agents is a routinely used assay format for p

45 argeting of pharmaceutical, therapeutic, and diagnostic agents is at the forefront of projects in nan

46 biologics and biosimilars as therapeutic and diagnostic agents is giving rise to new demands for anal

47 or the design of metal-based therapeutic and diagnostic agents, macrocycles are rigid enough to provi

48 their capacity to carry other therapeutic or diagnostic agents may potentially offer capabilities for

49 ence of modified proteins as therapeutic and diagnostic agents, methods for electrochemical modificat

50 These products can serve as diagnostic agents or provide key information about the i

51 encapsulating and delivering therapeutic and diagnostic agents, otherwise limited by poor pharmacokin

52 herefore, we have begun to evaluate novel AD diagnostic agents that can be radiolabeled with (64)Cu,

53 nanoparticles containing therapeutic and/or diagnostic agents that can bind to the bispecific protei

54 e in mice using doses of the nanoparticulate diagnostic agents that fall under regulatory guidelines

55 besin peptide analogues results in promising diagnostic agents that retain high receptor binding acti

56 ide a powerful tool for evaluating drugs and diagnostic agents that target the various pathways influ

57 (89)Zr-labeled SC16 antibody as a companion diagnostic agent to facilitate selection of patients for

58 eptides for the transport of therapeutic and diagnostic agents to acidic tissue sites associated with

59 ool for targeted delivery of therapeutic and diagnostic agents to breast cancers and perhaps other ty

60 By connecting cell-based diagnostic agents to ultrasound, these probiotic biosens

61 nge of affinities for many amyloid-targeting diagnostic agents under current development.

62 ing a specific cancer treatment methodology, diagnostic agents undertake a critical role.

63 al packaging and delivery of therapeutic and diagnostic agents, were constructed using a quick and ef

64 ate that the SAbetaO nanobody can serve as a diagnostic agent with potential theragnostic application